Ollin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedMC
Mubadala Capital
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
Mubadala Capital is the investment manager whose official portfolio includes Ollin, Alloy, Juvena and Crusoe.
Recorded funding activity
Ollin develops retinal-disease antibodies. Alloy supplies discovery platforms and services, while Crusoe develops computing infrastructure. The manager remains separate from Mubadala Investment Company; the Precision Neuroscience relation stays in draft.
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $403.5M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionAlloy Therapeutics
Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners.
$40MSeries E
Role not disclosedJuvena Therapeutics
Develops regenerative biologics to restore tissue function
$33.5MSeries B
Role not disclosed